Last Updated: 8/19
Share or print this information to talk to your doctor about this trial.
The primary purpose of this proof of concept clinical study is to evaluate the efficacy and safety of the study drug ACH-0144471 in participants who have been diagnosed with either C3GN or dense deposit disease (DDD) based on renal biopsy. Participants will be randomized 1:1 to receive either study drug ACH-0144471 or placebo for a period of 6 months.
Active, not recruiting
17 to 65
NOTE: Additional inclusion/exclusion criteria will apply, per protocol.
Children’s Hospital of Colorado
Aurora, CO 80045
Georgia Nephrology Center
Atlanta, GA 30046
University of Iowa
Iowa City, IA 52242
Baltimore, MD 21287
Mayo Clinic Rochester
Rochester, MN 55905
New York, NY 10032
New York University School of Medicine
Queens, NY 11040
Northeast Clinical Research Center
Bethlehem, PA 18017
Baylor College of Medicine
Houston, TX 77030
Imperial College of London
Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.
Clinical Operations | 203-752-5566
View complete study information on ClinicalTrials.gov
Thank you for visiting WeC3GTM
You are now leaving the WeC3G.com website and being directed to a third-party website. Achillion Pharmaceuticals, Inc. is not responsible for the content of the site you are about to visit.
Would you like to continue?
Continued use of this site indicates you have accepted this policy.